基于网络药理学的仁青芒觉胶囊治疗代谢性疾病作用机制研究
|
摘要
目的:基于网络药理学方法,初步探讨仁青芒觉胶囊的治疗代谢性疾病的功效物质基础和配伍作用机制。方法:依托中药系统药理学数据库和分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP),检索仁青芒觉胶囊中12味中药的化学成分和作用靶点;通过治疗靶点数据库(therapeutic target database,TTD),检索代谢性疾病的靶点;构建"化合物-靶点"网络、"靶点-通路"网络,研究仁青芒觉胶囊治疗代谢性疾病的作用机制,最终筛选出仁青芒觉可能的有效成分和靶点。结果:共检索出仁青芒觉胶囊治疗代谢性疾病潜在的可能靶点38个,其中,高脂血症相关靶点1个(3-羟基3-甲基戊二酰辅酶A还原酶),高尿酸血症相关靶点1个(黄嘌呤脱氢酶),糖尿病相关靶点36个;涉及通路8条,包括查加斯病、Toll样受体信号通路、肿瘤坏死因子信号通路、胰岛素抵抗、军团杆菌病、非酒精脂肪肝、T细胞受体信号通路和流行性感冒A。结论:本研究结果初步验证了仁青芒觉胶囊治疗代谢性疾病的基本药理作用及其作用机制,为进一步深入揭示其作用机制奠定了良好基础。
OBJECTIVE: To tentatively investigate the mechanism of functional material basis and compatibility mechanism of Renqingmangjue capsules in treatment of metabolic disease based on network pharmacology. METHODS: Traditional Chinese medicine systems pharmacology database and analysis platform(TCMSP) was retrieved for the chemical constituents and action targets of 12 traditional Chinese medicines in Renqingmangjue capsules. The therapeutic target database(TTD) was used to retrieve the metabolic disease targets. The compound-target network and target-pathway network were constructed to study the mechanism of Renqingmangjue capsules in treatment of metabolic disease, and finally the possible active components and targets of Renqingmangjue capsules were screened out. RESULTS: A total of 38 potential targets of Renqingmangjue capsules in treatment of metabolic disease were retrieved, including 1 target related to hyperlipidemia(3-hydroxy 3-methyl glutaryl coenzyme A reductase), 1 target related to hyperuricemia(xanthine dehydrogenase), and 36 targets related to diabetes. There were 8 pathways involved, including Chagas disease, Toll-like receptor signaling pathway, tumor necrosis factor signaling pathway, insulin resistance, legion Bacterial disease, nonalcoholic fatty liver, T cell receptor signaling pathway and influenza A. CONCLUSIONS: The results of this study preliminarily verify the basic pharmacological action and mechanism of Renqingmangjue capsules in treatment of metabolic disease, which lay a solid foundation for further studies on the mechanism of action.
OBJECTIVE: To tentatively investigate the mechanism of functional material basis and compatibility mechanism of Renqingmangjue capsules in treatment of metabolic disease based on network pharmacology. METHODS: Traditional Chinese medicine systems pharmacology database and analysis platform(TCMSP) was retrieved for the chemical constituents and action targets of 12 traditional Chinese medicines in Renqingmangjue capsules. The therapeutic target database(TTD) was used to retrieve the metabolic disease targets. The compound-target network and target-pathway network were constructed to study the mechanism of Renqingmangjue capsules in treatment of metabolic disease, and finally the possible active components and targets of Renqingmangjue capsules were screened out. RESULTS: A total of 38 potential targets of Renqingmangjue capsules in treatment of metabolic disease were retrieved, including 1 target related to hyperlipidemia(3-hydroxy 3-methyl glutaryl coenzyme A reductase), 1 target related to hyperuricemia(xanthine dehydrogenase), and 36 targets related to diabetes. There were 8 pathways involved, including Chagas disease, Toll-like receptor signaling pathway, tumor necrosis factor signaling pathway, insulin resistance, legion Bacterial disease, nonalcoholic fatty liver, T cell receptor signaling pathway and influenza A. CONCLUSIONS: The results of this study preliminarily verify the basic pharmacological action and mechanism of Renqingmangjue capsules in treatment of metabolic disease, which lay a solid foundation for further studies on the mechanism of action.
引文
[1] 房少新,赵利平.藏药仁青芒觉中微量元素的测定[J].光谱实验室,2013,30(2):916-919.
[2] 俄措卓玛.藏药仁青芒觉治疗慢性胃炎临床疗效观察[J].世界最新医学信息文摘,2017,17(13):175-176.
[3] 索郎.藏医药治疗消化道的临床观察[J].中国民族医药杂志,2015,21(5):21-22.
[4] 程体娟,杨军英,朱玲,等.仁青芒觉胶囊的耐缺氧及抗心律失常作用[J].中药药理与临床,2003,19(2):40-41.
[5] 董国锋,屠荣,刘云涛.血清对氧磷酶3影响代谢性疾病相关机制研究进展[J].生命的化学,2018,38(6):821-826.
[6] 孔令东,郝海平,郭淑贞,等.中西医结合防治代谢性疾病的关键科学问题[J].中国科学基金,2018,32(4):434-441.
[7] 黄国东,孙秀玉,陈书,等.网络药理学在国内中药复方研究的应用概况[J].广西中医药大学学报,2016,19(1):104-107.
[8] 周文霞.网络药理学的研究进展和发展前景[J].中国药理学与毒理学杂志,2015,29(5):760-762.
[9] 刘鑫馗,吴嘉瑞,蔺梦娟,等.基于网络药理学的四君子汤作用机制分析[J].中国实验方剂学杂志,2017,23(16):194-202.
[10] 刘鑫馗,吴嘉瑞,蔺梦娟,等.基于网络药理学的吴茱萸汤作用机制分析[J].中国实验方剂学杂志,2017,23(16):203-210.
[11] 任真真,张燕玲,王星,等.三七皂苷类成分的蛋白质相互作用网络分析[J].中国中药杂志,2014,39(11):2097-2101.
[12] 霍梦琪,张燕玲,郑世超,等.基于共表达蛋白相互作用网络探讨川芎嗪治疗冠心病的机制[J].北京中医药大学学报,2016,39(12):989-997.
[13] 李丕栋.基于系统生物学的肝癌分子机制及护肝片治作用研究[D].咸阳:西北农林科技大学,2016.
[14] 彭萍.冠心病与风险基因ABCG1、GALNT2、HMGCR启动子区甲基化关系的研究[D].宁波:宁波大学,2014.
[15] 孟珂.脂质关键基因在不同药物预防胆囊胆固醇结石中的作用机理[D].天津:天津医科大学,2017.
[16] 朱明敏.复方土茯苓颗粒对高尿酸血症黄嘌呤氧化酶的抑制作用[D].广州:广州中医药大学,2015.
[17] 祖克拉·肉孜(Ruzi Zohra).新疆柯尔克孜族人群PPARG基因重组热点遗传定位及糖尿病关联研究[D].乌鲁木齐:新疆大学,2015.
[18] 毛丹丹.PPARG基因多态性与摄入鲜榨蔬果汁对肥胖个体轻断食减重效果的影响[J].临床医药文献电子杂志,2018,5(64):193-194.
[19] 官鑫.雌激素受体α基因多态性与2型糖尿病的关系[D].长春:吉林大学,2010.
[20] 冯林林.DPP-4基因多态性与T2DM的相关性及对西格列汀治疗2型糖尿病疗效的影响研究[D].泸州:西南医科大学,2018.
[21] 王谦.沙棘籽渣中五种黄酮类化合物对脂代谢的调控及机理探究[D].上海:华东师范大学,2014.
[22] 李博,吴媛媛,屠幼英.表没食子儿茶素没食子酸酯(EGCG)的体内外转化及产物活性研究进展[J].天然产物研究与开发,2010,22(2):351-355,318.
[23] 朱亚军.Toll样受体家族与高脂血症和胰岛素抵抗的相关性研究[D].石家庄:河北医科大学,2014.
[24] 柯淑红,郑承红,彭聪,等.非酒精性脂肪性肝病合并2型糖尿病大鼠模型的建立[J].世界华人消化杂志,2018,26(31):1805-1811.
[25] 刘璐,曹世杰,程丽娜,等.肿瘤坏死因子-α诱导脂肪细胞胰岛素抵抗模型的建立及评价指标[J].天津中医药,2018,35(11):848-853.
[2] 俄措卓玛.藏药仁青芒觉治疗慢性胃炎临床疗效观察[J].世界最新医学信息文摘,2017,17(13):175-176.
[3] 索郎.藏医药治疗消化道的临床观察[J].中国民族医药杂志,2015,21(5):21-22.
[4] 程体娟,杨军英,朱玲,等.仁青芒觉胶囊的耐缺氧及抗心律失常作用[J].中药药理与临床,2003,19(2):40-41.
[5] 董国锋,屠荣,刘云涛.血清对氧磷酶3影响代谢性疾病相关机制研究进展[J].生命的化学,2018,38(6):821-826.
[6] 孔令东,郝海平,郭淑贞,等.中西医结合防治代谢性疾病的关键科学问题[J].中国科学基金,2018,32(4):434-441.
[7] 黄国东,孙秀玉,陈书,等.网络药理学在国内中药复方研究的应用概况[J].广西中医药大学学报,2016,19(1):104-107.
[8] 周文霞.网络药理学的研究进展和发展前景[J].中国药理学与毒理学杂志,2015,29(5):760-762.
[9] 刘鑫馗,吴嘉瑞,蔺梦娟,等.基于网络药理学的四君子汤作用机制分析[J].中国实验方剂学杂志,2017,23(16):194-202.
[10] 刘鑫馗,吴嘉瑞,蔺梦娟,等.基于网络药理学的吴茱萸汤作用机制分析[J].中国实验方剂学杂志,2017,23(16):203-210.
[11] 任真真,张燕玲,王星,等.三七皂苷类成分的蛋白质相互作用网络分析[J].中国中药杂志,2014,39(11):2097-2101.
[12] 霍梦琪,张燕玲,郑世超,等.基于共表达蛋白相互作用网络探讨川芎嗪治疗冠心病的机制[J].北京中医药大学学报,2016,39(12):989-997.
[13] 李丕栋.基于系统生物学的肝癌分子机制及护肝片治作用研究[D].咸阳:西北农林科技大学,2016.
[14] 彭萍.冠心病与风险基因ABCG1、GALNT2、HMGCR启动子区甲基化关系的研究[D].宁波:宁波大学,2014.
[15] 孟珂.脂质关键基因在不同药物预防胆囊胆固醇结石中的作用机理[D].天津:天津医科大学,2017.
[16] 朱明敏.复方土茯苓颗粒对高尿酸血症黄嘌呤氧化酶的抑制作用[D].广州:广州中医药大学,2015.
[17] 祖克拉·肉孜(Ruzi Zohra).新疆柯尔克孜族人群PPARG基因重组热点遗传定位及糖尿病关联研究[D].乌鲁木齐:新疆大学,2015.
[18] 毛丹丹.PPARG基因多态性与摄入鲜榨蔬果汁对肥胖个体轻断食减重效果的影响[J].临床医药文献电子杂志,2018,5(64):193-194.
[19] 官鑫.雌激素受体α基因多态性与2型糖尿病的关系[D].长春:吉林大学,2010.
[20] 冯林林.DPP-4基因多态性与T2DM的相关性及对西格列汀治疗2型糖尿病疗效的影响研究[D].泸州:西南医科大学,2018.
[21] 王谦.沙棘籽渣中五种黄酮类化合物对脂代谢的调控及机理探究[D].上海:华东师范大学,2014.
[22] 李博,吴媛媛,屠幼英.表没食子儿茶素没食子酸酯(EGCG)的体内外转化及产物活性研究进展[J].天然产物研究与开发,2010,22(2):351-355,318.
[23] 朱亚军.Toll样受体家族与高脂血症和胰岛素抵抗的相关性研究[D].石家庄:河北医科大学,2014.
[24] 柯淑红,郑承红,彭聪,等.非酒精性脂肪性肝病合并2型糖尿病大鼠模型的建立[J].世界华人消化杂志,2018,26(31):1805-1811.
[25] 刘璐,曹世杰,程丽娜,等.肿瘤坏死因子-α诱导脂肪细胞胰岛素抵抗模型的建立及评价指标[J].天津中医药,2018,35(11):848-853.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |